Strategies to improve non-viral vectors - Potential applications in clinical transplantation

Expert Opinion on Biological Therapy

Volumn 6, Issue 6, 2006, Pages 619-630

  Tan, P H ^a,b   Chan, C L H ^c   George, A J T ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Dendrimers; Gene therapy; Immunology; Liposomes; Non viral vectors; Polymers; Transplantation

Indexed keywords

COMPLEMENTARY DNA; DENDRIMER; FAS ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; POLYMER; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; VIRUS VECTOR;

ALLOGRAFT; CELL DAMAGE; CELL MANIPULATION; CLINICAL TRIAL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE FUNCTION; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; META ANALYSIS; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; SYSTEMATIC REVIEW; TISSUE PRESERVATION; TISSUE TRANSPLANTATION; TRANSGENE;

ANIMALS; GENE THERAPY; GENETIC VECTORS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE SYSTEM; INFLAMMATION; MODELS, BIOLOGICAL; TRANSPLANTATION;

ANIMALIA;

EID: 33744822724     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.6.619     Document Type: Review

References (100)

1. TAN PH, CHAN CL, CHAN C, GEORGE AJ: The evolving role of gene-based treatment in surgery. Br. J. Surg. (2005) 92(12):1466-1480. This review provides a comprehensive overview on the success story of gene therapy as a treatment modality in surgical diseases, including transplantation surgery.
2. JAESCHKE H, SMITH CW, CLEMENS MG, GANEY PE, ROTH RA: Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Toxicol. Appl. Pharmacol. (1996) 139(2):213-226.
3. YAMAGUCHI Y, MATSUMURA F, TAKEYA M et al.: Monocyte chemoattractant protein-1 enhances expression of intercellular adhesion molecule-1 following ischemia-reperfusion of the liver in rats. Hepatology (1998) 27(3):727-734.
4. FANSLOW WC, SIMS JE, SASSENFELD H et al.: Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science (1990) 248(4956):739-742. This work highlights that the prolongation of allograft survival can be achieved using the soluble form of IL-1 receptor through the neutralisation of IL-1 interaction with its receptor.
5. RAYNER SA, LARKIN DF, GEORGE AJ: TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest. Ophthalmol. Vis. Sci. (2001) 42(7):1568-1573. This is an important in vivo demonstration that the use of adenovirus as a carrier for an immunomodulatory gene can interfere with the function of its immune modulation. This may be attributed to the immunogenicity of adenovirus in vivo.
6. ZEHR KJ, HERSKOWITZ A, LEE PC et al.: Neutrophil adhesion and complement inhibition prolongs survival of cardiac xenografts in discordant species. Transplantation (1994) 57(6):900-906.
7. ROTH C, KOURILSKY P, OJCIUS DM: Ly-49-independent inhibition of natural killer cell-mediated cytotoxicity by a soluble major histocompatibility complex class I molecule. Eur. J. Immunol. (1994) 24(9):2110-2114.
8. KONDO S, YIN D, MORIMURA T et al.: Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppression. Cancer Res. (1994) 54(11):2928-2933.
9. ZWACKA RM, ZHOU W, ZHANG Y et al.: Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation. Nat. Med. (1998) 4(6):698-704. This study highlights the fact that gene-based interference of redox mechanisms can modulate the effect of ischaemia and reperfusion injury. The study also highlights the main pathways that may be attributed to ischaemia and reperfusion injury.
10. SPRINGER TA: Adhesion receptors of the immune system. Nature (1990) 346(6283):425-434.
11. ISOBE M, YAGITA H, OKUMURA K, IHARA A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science (1992) 255(5048):1125-1127. This work provides the first evidence of the role of ICAM-1 and LFA-1 in mediating transplant rejection. The blockade of the ICAM-1/LFA-1 interaction can induce the allograft tolerance.
12. QIN L, CHAVIN KD, DING Y et al.: Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGF-beta 1 or vIL-10. Transplantation (1995) 59(6):809-816.
13. DEBRUYNE LA, LI K, CHAN SY et al.: Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther. (1998) 5(8):1079-1087.
14. HANCOCK WW, SAYEGH MH, ZHENG XG et al.: Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA (1996) 93(24):13967-13972.
15. LENSCHOW DJ, ZENG Y, THISTLETHWAITE JR et al.: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science (1992) 257(5071):789-792. This paper demonstrates the role of costimulation in mediating transplant rejection. Blockade of the CD28 and CD80/S6 interaction can result in the long-term survival of xenogeneic grafts.
16. COMER RM, KING WJ, ARDJOMAND N et al.: Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest. Ophthalmol. Vis. Sci. (2002) 43(4):1095-1103.
17. GROHMANN U, ORABONA C, FALLARINO F et al.: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. (2002) 3(11):1097-1101. First evidence indicating that the use of CTLA4-Ig not only blocks the CD28 and CD80/86 interaction, but also induces the action of IDO. The role of upregulation of IDO may be attributed to the prolongation of allogeneic pancreatic graft in vivo.
18. ALEXANDER AM, CRAWFORD M, BERTERA S et al.: Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diaberogenic splenocytes. Diabetes (2002) 51(2):356-365.
19. BEUTELSPACHER SC, PILLAI R, WATSON M et al.: Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur. J. Immunol. (2006) 36(3):690-700.
20. GAINER AL, SUAREZ-PINZON WL, MIN WP et al.: Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation (1998) 66(2):194-199.
21. TAN PH, BEUTELSPACHER SC, WANG YH et al.: Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol. Ther. (2005) 11(5):790-800. An important study demonstrating use of a novel non-viral vector to mediate gene transfer to dendritic cells. Using this vector, the authors successfully transduce the dendritic cells with the IDO gene, indicating that the IDO gene can induce T cell tolerance through the induction of T cell apoptosis and anergy via IL-10-dependent action.
22. LU L, LEE WC, TAKAYAMA T et al.: Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig). J. Leukoc. Biol. (1999) 66(2):293-296.
23. LU L, QIAN S, HERSHBERGER PA et al.: Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. (1997) 158(12):5676-5684.
24. TAN PH, YATES JB, XUE SA et al.: Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood (2005) 106(9):2936-2943. Costimulation is important for T cell activation. It has therefore been proposed that the lack of CD80/86 is the direct cause of tolerance induced by immature dendritic cells. However, there has been little firm experimental evidence available to directly support this hypothesis. To help clarify this, this paper brings about the novel strategy of binding and destroying the CD80/86 in dendritic cells before its expression on the cell surface. The work offers novel support for the hypothesis that the absence of CD80/86 expression can render dendritic cells tolerogenic. From a therapeutic standpoint, the work also suggests a novel strategy that might render human monocyte-derived dendritic cells tolerogenic in vivo.
25. BRADLEY JA, BOLTON EM, PEDERSEN RA: Stem cell medicine encounters the immune system. Nat. Rev. Immunol. (2002) 2(11):859-871.
26. MANN MJ, GIBBONS GH, HUTCHINSON H et al.: Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc. Natl. Acad. Sci. USA (1999) 96(11):6411-6416.
27. LIU F, SONG Y, LIU D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. (1999) 6(7):1258-1266.
28. YANG NS, BURKHOLDER J, ROBERTS B, MARTINELL B, MCCABE D: In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc. Natl. Acad. Sci. USA (1990) 87(24):9568-9572.
29. KODAMA T, TAN PH, OFFIAH I et al.: Delivery of oligodeoxynucleotides into human saphenous veins: the adjunct effect of ultrasound and microbubbles. Ultrasound Med. Biol. (2005) 31(12):1683-1691.
30. AIHARA H, MIYAZAKI J: Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. (1998) 16(9):867-870.
31. VILLANUEVA FS, JANKOWSKI RJ, KLIBANOV S et al.: Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation (1998) 98(1):1-5.
32. FELGNER PL, GADEK TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA (1987) 84(21):7413-7417.
33. RANGARAJAN PN, VATSALA PG, ASHOK MS et al.: Non-viral ex vivo hepatic gene transfer by in situ lipofection of liver and intraperitoneal transplantation of hepatocytes. Gene (1997) 190(1):217-221.
34. BENIGNI A, TOMASONI S, REMUZZI G: Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. Kidney Int. (2002) 61(1 Suppl.):115-119.
35. BENHAMOU PY, MORISCOT C, PREVOST P et al.: Standardization of procedure for efficient ex vivo gene transfer into porcine pancreatic islets with cationic liposomes. Transplantation (1997) 63(12):1798-1803.
36. WAGNER E, OGRIS M, ZAUNER W: Polylysine-based transfection systems utilizing receptor-mediated delivery. Adv. Drug Deliv. Rev. (1998) 30(1-3):97-113.
37. KIM JS, MARUYAMA A, AKAIKE T, KIM SW: Terplex DNA delivery system as a gene carrier. Pharm. Res. (1998) 15(1):116-121.
38. WU CH, WILSON JM, WU GY: Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J. Biol. Chem. (1989) 264(29):16985-16987.
39. SCHAFFER DV, LAUFFENBURGER DA: Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery. J. Biol. Chem. (1998) 273(43):28004-28009.
40. KUKOWSKA-LATALLO JF, BIELINSKA AU, JOHNSON J et al.: Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. USA (1996) 93(10):4897-4902.
41. TANG MX, REDEMANN CT, SZOKA FC JR: In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug. Chem. (1996) 7(6):703-714.
42. GODBEY WT, WU KK, HIRASAKI GJ, MIKOS AG: Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency. Gene Ther. (1999) 6(8):1380-1388.
43. DIEBOLD SS, KURSA M, WAGNER E, COTTEN M, ZENKE M: Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem. (1999) 274(27):19087-19094.
44. OGRIS M, STEINLEIN P, KURSA M et al.: The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Ther. (1998) 5(10):1425-1433.
45. QIN L, PAHUD DR, DING Y et al.: Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers. Hum. Gene Ther. (1998) 9(4):553-560.
46. TRUONG-LE VL, AUGUST JT LEONG KW: Controlled gene delivery by DNA-gelatin nanospheres. Hum. Gene Ther. (1998) 9(12):1709-1717.
47. VAN DE WETERING P, MORET EE, SCHUURMANS-NIEUWENBROEK NM, VAN STEENBERGEN MJ, HENNINK WE: Structure-activity relationships of water-soluble cationic methacrylare/methacrylamide polymers for nonviral gene delivery. Bioconjug. Chem. (1999) 10(4):589-597.
48. VAN DER WOUDE I, WAGENAAR A, MEEKEL AA et al.: Novel pyridinium surfactants for efficient, nontoxic in vitro gene delivery. Proc. Natl. Acad. Sci. USA (1997) 94(4):1160-1165.
49. SHEA LD, SMILEY E, BONADIO J, MOONEY DJ: DNA delivery from polymer matrices for tissue engineering. Nat. Biotechnol. (1999) 17(6):551-554.
50. GOLDFARB DS, GARIEPY J, SCHOOLNIK G, KORNBERG RD: Synthetic peptides as nuclear localization signals. Nature (1986) 322(6080):641-644.
51. TAN PH, BEUTELSPACHER SC, XUE SA et al.: Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood (2005) 105(10):3824-3832. This is an important paper that highlights the deficiencies of viral vectors. It shows that viral vectors can activate immature dendritic cells through the activation of NF-κB, phosphatidylinositol 3-kinase (PI3K) and double-stranded (ds)RNA-triggered protein kinase (PKR) pathways. On the other hand, exposure of mature dendritic cells to viral vectors can also upregulate IDO activity and modulate the immunostimulatory capacity of mature dendritic cells.
52. TAN PH, XUE SA, MANUNTA M et al.: Effect of vectors on human endothelial cell signal transduction: implications for cardiovascular gene therapy. Arterioscler. Thromb. Vasc. Biol. (2006) 26(3):462-467. Using endothelial cells as a model, this work demonstrates that viral vectors are more efficient than non-viral vectors at transferring genes. However, the viral vectors can activate NF-κB, PI3K and dsRNA-triggered/PKR pathways. In addition, the paper also shows that blockade of the NF-κB, PI3K or PKR signalling pathways all operated to inhibit partially virally induced activation, and inhibition of both PKR and PI3K pathways totally blocked endothelial cell activation.
53. HUDDE T, RAYNER SA, DE ALWIS M et al.: Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium. Cornea (2000) 19(3):369-373.
54. BEUTELSPACHER SC, ARDJOMAND N, TAN PH et al.: Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction. Exp. Eye Res. (2005) 80(6):787-794.
55. TAN PH, KING WJ, CHEN D et al.: Transferrin receptor-mediated gene transfer to the corneal endothelium. Transplantation (2001) 71(4):552-560.
56. TAN PH, MANUNTA M, ARDJOMAND N et al.: Antibody targeted gene transfer to endothelium. J. Gene Med. (2003) 5(4):311-323.
57. ZELPHATI O, SZOKA FC JR: Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA (1996) 93(21):11493-11498.
58. MANUNTA M, TAN PH, SAGOO P, KASHEFI K, GEORGE AJ: Gene delivery by dendrimers operates via a cholesterol dependent pathway. Nucleic Acids Res. (2004) 32(9):2730-2739. This paper points out that the role of cholesterol in the lipid raft is responsible for the binding and subsequent internalisation of non-viral vectors. This represents the first step towards the understanding of the process of vector internalisation.
59. POPIK W, ALCE TM, AU WC: Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J. Virol. (2002) 76(10):4709-4722.
60. ZENKE M, STEINLEIN P, WAGNER E et al.: Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc. Natl. Acad. Sci. USA (1990) 87(10):3655-3659.
61. COTTEN M, SALTIK M, KURSA M et al.: Psoralen treatment of adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid. Virology (1994) 205(1):254-261.
62. CRISTIANO RJ, SMITH LC, WOO SL: Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc. Natl. Acad. Sci. USA (1993) 90(6):2122-2126.
63. GOTTSCHALK S, CRISTIANO RJ, SMITH LC, WOO SL: Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Ther. (1994) 1(3):185-191.
64. ARANCIBIA-CARCAMO CV, ORAL HB, HASKARD DO, LARKIN DF, GEORGE AJ: Lipoadenofection-mediated gene delivery to the corneal endothelium: prospects for modulating graft rejection. Transplantation (1998) 65(1):62-67.
65. MICHAEL SI, HUANG CH, ROMER MU et al.: Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J. Biol. Chem. (1993) 268(10):6866-6869.
66. UHEREK C, FOMINAYA J, WELS W: A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery. J. Biol. Chem. (1998) 273(15):8835-8841.
67. MAHATO RI: Non-viral peptide-based approaches to gene delivery. J. Drug Target. (1999) 7(4):249-268.
68. CARR CM, KIM PS: A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell (1993) 73(4):823-832.
69. WAGNER E, ZATLOUKAL K, GOTTEN M et al.: Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc. Natl. Acad. Sci. USA (1992) 89(13):6099-6103.
70. DESHPANDE D, TOLEDO-VELASQUEZ D, THAKKAR D, LIANG W, ROJANASAKUL Y: Enhanced cellular uptake of oligonucleotides by EGF receptor-mediated endocytosis in A549 cells. Pharm. Res. (1996) 13(1):57-61.
71. PLANK C, ZATLOUKAL K, COTTEN M, MECHTLER K, WAGNER E: Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. Bioconjug. Chem. (1992) 3(6):533-539.
72. MIDOUX P, MENDES C, LEGRAND A et al.: Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. Nucleic Acids Res. (1993) 21(4):871-878.
73. PARENTE RA, NIR S, SZOKA FC JR: pH-dependent fusion of phosphatidylcholine small vesicles. Induction by a synthetic amphipathic peptide. J. Biol. Chem. (1988) 263(10):4724-4730.
74. WYMAN TB, NICOL F, ZELPHATI O et al.: Design, synthesis, and characterization of acationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry (1997) 36(10):3008-3017.
75. WOLFERT MA, SEYMOUR LW: Chloroquine and amphipathic peptide helices show synergistic transfection in vitro. Gene Ther. (1998) 5(3):409-414.
76. MOLLENHAUER HH, MORRE DJ, ROWE LD: Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim. Biophys. Acta (1990) 1031(2):225-246.
77. ROSENKRANZ AA, YACHMENEV SV, JANS DA et al.: Receptor-mediated endocytosis and nuclear transport of a transfecting DNA construct. Exp. Cell Res. (1992) 199(2):323-329.
78. ZAUNER W, KICHLER A, SCHMIDT W, SINSKI A, WAGNER E: Glycerol enhancement of ligand-polylysine/DNA transfection. Biotechniques (1996) 20(5):905-913.
79. FAJAC I, ALLO JC, SOUIL E et al.: Histidylated polylysine as a synthetic vector for gene transfer into immortalized cystic fibrosis airway surface and airway gland serous cells. J. Gene Med. (2000) 2(5):368-378.
80. HOGSET A, PRASMICKAITE L, TJELLE TE, BERG K: Photochemical transfection: a new technology for light-induced, site- directed gene delivery. Hum. Gene Ther. (2000) 11(6):869-880.
81. KATAYOSE S, KATAOKA K: Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer. Bioconjug. Chem. (1997) 8(5):702-707.
82. XU B, WIEHLE S, ROTH JA, CRISTIANO RJ: The contribution of poly-L-lysine, epidermal growth factor and streptavidin to EGF/PLL/DNA polyplex formation. Gene Ther. (1998) 5(9):1235-1243.
83. ROSS GF, BRUNO MD, UYEDA M et al.: Enhanced reporter gene expression in cells transfected in the presence of DMI-2, an acid nuclease inhibitor. Gene Ther. (1998) 5(9):1244-1250.
84. KALDERON D, RICHARDSON WD, MARKHAM AF, SMITH AE: Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature (1984) 311(5981):33-38.
85. BRANDEN LJ, MOHAMED AJ, SMITH CI: A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat. Biotechnol. (1999) 17(8):784-787.
86. ZIEMIENOWICZ A, GORLICH D, LANKA E, HOHN B, ROSSI L: Import of DNA into mammalian nuclei by proteins originating from a plant pathogenic bacterium. Proc. Natl. Acad. Sci. USA (1999) 96(7):3729-3733.
87. YANT SR, MEUSE L, CHIU W et al.: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat. Genet. (2000) 25(1):35-41.
88. ORTIZ-URDA S, LIN Q, YANT SR et al.: Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther. (2003) 10(13):1099-1104.
89. OLIVARES EC, HOLLIS RP, CHALBERG TW et al.: Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat. Biotechnol. (2002) 20(11):1124-1128.
90. BOSHART M, WEBER F, JAHN G et al.: A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell (1985) 41(2):521-530.
91. ADACHI Y, REYNOLDS PN, YAMAMOTO M et al.: Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res. (2000) 60(16):4305-4310.
92. SHI N, ZHANG Y, ZHU C, BOADO RJ, PARDRIDGE WM: Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. USA (2001) 98(22):12754-12759.
93. REYNOLDS PN, NICKLIN SA, KALIBEROVA L et al.: Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat. Biotechnol. (2001) 19(9):838-842.
94. MORISHITA K, JOHNSON DE, WILLIAMS LT: A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J. Biol. Chem. (1995) 270(46):27948-27953.
95. ALLEN TM, HANSEN C, MARTIN F, REDEMANN C, YAU-YOUNG A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta (1991) 1066(1):29-36.
96. OGRIS M, BRUNNER S, SCHULLER S, KIRCHEIS R, WAGNER E: PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. (1999) 6(4):595-605.
97. JONES DH, CORRIS S, MCDONALD S, CLEGG JC, FARRAR GH: Poly(DL-lactide-co- glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine (1997) 15(8):814-817.
98. LUO D, WOODROW-MUMFORD K, BELCHEVA N, SALTZMAN WM: Controlled DNA delivery systems. Pharm. Res. (1999) 16(8):1300-1308.
99. FELGNER PL, RINGOLD GM: Cationic liposome-mediated transfection. Nature (1989) 337(6205):387-388.
100. MORRAL N, O'NEAL W, RICE K et al.: Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA (1999) 96(22):12816-12821.